Crohn’s Disease News and Research

RSS

Cannabis drugs may benefit those with bowel disease

UK scientists say they believe that patients with inflammatory bowel disease may benefit from cannabis-based drugs.

1 Aug 2005

Loyola researchers hope that zoledronic acid will be effective and safe for patients with inflammatory bowel diseases (IBD)

Researchers at the Osteoporosis and Metabolic Bone Disease Center and the Division of Gastroenterology at Loyola University Health System are studying a once-yearly, 15-minute infusion of an intravenous (IV) medication in patients with osteopenia (low bone mass) and inflammatory bowel diseases (IBD) that, if proven effective, may be considered the standard of treatment.

26 Jul 2005

Camera-guided surgery through small incisions works better than conventional surgery for colon cancer

Camera-guided surgery through small incisions works better than conventional surgery for colon cancer and related diseases, at least in the short term recovery, a new review of previous studies confirms. In the long term, researchers found no difference between the two.

19 Jul 2005

Research explains one of the fundamental mysteries of multiple sclerosis

Scientists have pinpointed a chemical messenger that frees some white blood cells from the body's normal constraints, allowing the cells to act like renegades that could damage nerves in the central nervous system. The work, to be published in the July 15 issue of the Journal of Immunology and just published on-line, helps explain one of the fundamental mysteries of multiple sclerosis (MS).

11 Jul 2005

FDA approves treatment for diarrhea caused by Cryptosporidium infection

The U.S. Food and Drug Administration (FDA) has approved Alinia (nitazoxanide) tablets and oral suspension for treating diarrhea caused by Cryptosporidium parvum infection in adults and children 12 years and older. The product, already approved to treat the same infection in younger children, received a priority review by FDA.

19 Jun 2005

Multiple sclerosis drug Tysabri could be back on the market later in the year

The drug Tysabri which was approved by the Food and Drug Administration (FDA) for the treatment of multiple sclerosis in November 2004, was taken off the market in late February, after two cases of progressive multifocal leukoencephalopathy, or PML, appeared in patients given the drug during clinical trials.

9 Jun 2005

Stimulating innate immunity helps ease Crohn's disease symptoms

Like throwing oil on a fire or prescribing a high cholesterol diet for heart patients, gastroenterologists traditionally have believed that it would not be a good idea to stoke up the body's immune system to treat Crohn's disease.

26 May 2005

No link between MMR jab and Crohn's disease

A research paper published in 1998, which claimed the MMR jab was in some way linked to autism and Crohn's disease, the inflammatory bowel disease, caused MMR vaccination numbers to fall across the country.

12 May 2005

Discovery of gene STAT6(B) may lead to new treatments for inflammatory diseases

In a paper featured in Proceedings of the National Academy of Science (PNAS), researchers from Boston University School of Dental Medicine report the discovery of a new gene, STAT6(B), that helps regulate production of the potentially deadly tumor necrosis factor alpha (TNF-alpha) cytokine.

28 Mar 2005

Vital molecular step in cell migration

A vital molecular step in cell migration, the movement of cells within the body during growth, tissue repair and the body's immune response to invading pathogens, has been demonstrated by researchers in the University of California, San Diego (UCSD) School of Medicine.

28 Mar 2005

Calcium and vitamin D treatment alone can improve bone mineral density in Crohn's patients

According to a study published today in the American Gastroenterological Association (AGA) journal Clinical Gastroenterology and Hepatology, the addition of popular bone building drugs to calcium and vitamin D therapy to treat bone loss associated with Crohn's disease is not beneficial.

1 Feb 2005

Biochip for detection of inflammatory bowel disease

At the III International Symposium on Advanced Therapy for Chronic Inflammatory Bowel Disease, held in Madrid, the biotechnological company, Progenika, presented a DNA-chip the purpose of which is the optimisation of the diagnosis, prognosis and treatment of patients with inflammatory bowel disease (Crohn’s disease and Ulcerous Colitis).

26 Jan 2005

Monoclonal antibody therapeutics to fill vacuum left by ineffective conventional therapies

Currently, the limited efficacy of conventional therapies, especially in the case of several oncology and autoimmune and inflammatory disorders (AIID), is creating the need for safe and effective treatment alternatives.

25 Jan 2005

Small is beautiful in the medical world

Small is beautiful in the medical world. And being able to give European industry the edge in a nearly €200 billion worldwide biomedical market is what drives a consortium of EU-backed partners to make and market smaller, cheaper and better biomedical devices and innovative new applications.

19 Jan 2005

New findings clarify the role of NOD2, a key molecular player in Crohn's Disease

This week, researchers report new findings that clarify the role of NOD2, a key molecular player in Crohn's Disease, in the cellular signaling pathways that control inflammatory responses. NOD2's clinical relevance is clear from the fact that it is encoded by a Crohn's Disease susceptibility gene.

28 Dec 2004

Parasitic worms, or helminths, may be an effective treatment for Crohn's disease

Helminths, such as roundworms and threadworms, are rare in developed countries, where rates of Crohn's disease are high. But in developing countries where corresponding rates of the disease are low, many people carry these parasitic worms.

13 Dec 2004

FDA approval of Tysabri, for the treatment of multiple sclerosis

Biogen and Elan Corporation have announced that the U.S. Food and Drug Administration (FDA) has approved Tysabri (natalizumab), as treatment for relapsing forms of multiple sclerosis (MS) to reduce the frequency of clinical relapses.

24 Nov 2004

Abbott's investigational anti-interleukin-12 fully human monoclonal antibody in Crohn's disease study

Results of a Phase II study of Abbott's ABT-874, a fully human anti-interleukin-12 (IL-12) monoclonal antibody, will appear tomorrow in the New England Journal of Medicine citing treatment with ABT-874 shows differences in response and remission in patients with active Crohn's disease compared to placebo, in one arm of the study.

10 Nov 2004

New studies demonstrate efficacy of novel Lipoxin analog in laboratory models of Crohn's disease

Berlex announced today that new laboratory results demonstrate that its modified version of the naturally occurring lipoxin molecule exerts potent anti-inflammatory and immunomodulatory effects in Crohn's disease in vivo models and may provide a promising new oral treatment.

9 Nov 2004

Analysis shows Remicade reduces pain associated with Crohn's disease

According to a new sub-analysis from the ACCENT I (A Crohn's disease Clinical trial Evaluating infliximab in a New long-term Treatment regimen) trial patients who received a three-dose induction regimen of Remicade experienced a significantly greater reduction in pain as assessed by four different pain questions after ten weeks, compared with patients who received a single dose of Remicade.

2 Nov 2004